Table 1.

Return to normal status or awakening within 30 minutes after nasal glucagon administration in the efficacy analysis population

Patients who experienced ≥1 moderate/severe HE (number of patients, N = 69)
Number of patients who awakened or returned to normal status within 30 min in at least 1 evaluable event (%)	66 (95.7)
Number of patients who awakened or returned to normal status within 30 min in all evaluable events (%)	64 (92.8)
Moderate/severe HEs (number of events, N = 157)
Number of HEs in which patients awakened or returned to normal status within 30 min (%)	151 (96.2)a
Severe HEs (n = 12)
Time to awaken from severe event where patient was unconscious or had convulsions (n = 10)b, n (%)
<5 min	1 (10.0)
5 to <10 min	6 (60.0)
10 to <15 min	3 (30.0)
Time to return to normal status from severe event where patient was conscious (n = 2)c, n (%)
5 to <10 min	2 (100)
Moderate HEs (n = 145)
Time to return to normal statusd, n (%)
<5 min	27 (18.6)
5 to <10 min	43 (29.7)
10 to <15 min	33 (22.8)
15 to <20 min	23 (15.9)
20 to <25 min	7 (4.8)
25 to <30 min	6 (4.1)
30 to <45 min	5 (3.4)
Other	1e (0.7)

Abbreviations: HE, hypoglycaemic event; NG, nasal glucagon.

^aDetails regarding the 6 HEs in which patients did not return to normal status within 30 min are presented in Table S2.

^bPercentages based on the total number of events where “Time to awaken from severe event where patient was unconscious or had convulsions” was reported (n = 10).

^cPercentages based on the total number of events where “Time to return to normal status from severe event where patient was conscious” was reported (n = 2).

^dPercentages based on the total number of moderate events (n = 145).

^eIn this HE, the patient reported persistent headache, which prevented the patient from returning to normal status.